LOS ANGELES--(BUSINESS WIRE)--June 28, 2006--Abraxis BioScience, Inc. (NASDAQ:ABBI - News), an integrated, global biopharmaceutical company, today announced it has completed its acquisition of the AstraZeneca (NYSE:AZN - News) U.S. branded anesthetic and analgesic injectable product portfolios. Abraxis will have agreements with most major Group Purchasing Organizations (GPOs), representing the majority of U.S. hospitals, and will assume responsibility for over 700 individual contracts for this portfolio of drugs. Products in this acquisition encompass over 100 dosage forms and include the leading branded anesthetic agent, Diprivan® (propofol), and Naropin® (ropivacaine), as well as a comprehensive suite of local anesthetics including EMLA® Cream (Eutectic Mixture of Lidocaine and Prilocaine), Xylocaine® (lidocaine), Polocaine® (mepivacaine), Nesacaine® (chloroprocaine HCl Injection, USP), Sensorcaine® (bupivacaine), and Astramorph® (morphine sulfate injection, USP). On April 26, 2006, Abraxis announced the execution of a definitive agreement to acquire these products.
